Tsutsui T, Watanabe E, Barrett J C
Department of Pharmacology, Nippon Dental University, School of Dentistry, Tokyo, Japan.
Carcinogenesis. 1993 Apr;14(4):611-8. doi: 10.1093/carcin/14.4.611.
Di(2-ethylhexyl)phthalate (DEHP), a commonly used plasticizer, induces proliferation of peroxisomes in liver cells and causes hepatocellular carcinomas when chronically administered in the diet to rodents. To examine possible mechanisms for DEHP-associated cancer, we have measured induction of morphological transformation, chromosome aberrations and peroxisome proliferations of cultured Syrian hamster embryo (SHE) cells by DEHP and other peroxisome proliferators. Morphological transformation of SHE cells was weakly induced by treatment for 48 h with DEHP and its metabolite mono(2-ethylhexyl)phthalate (MEHP). The transformation frequency by DEHP was enhanced by exogenous metabolic activation using rat liver postmitochondrial supernatants. Treatment for 24 h with DEHP resulted in chromosome aberrations of the cells only in the presence of exogenous metabolic activation. 2-(p-chlorophenoxy)-2-methylpropionic acid ethyl ester (clofibrate), a widely used hypolipidemic drug, failed to induce morphological transformation or chromosome aberrations of SHE cells. Treatment with [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643), which is a more potent carcinogen than DEHP or clofibrate, elicited a lower frequency of morphological transformation than DEHP in the presence of exogenous metabolic activation but was more active than DEHP at inducing chromosome aberrations. Similar levels of peroxisome proliferation, as determined by an intensity of diaminobenzidine staining, were observed in cultures treated for 2 h with DEHP, MEHP, clofibrate or WY-14,643. These results suggest a possible involvement of genetic damage by DEHP metabolites in the induction of cell transformation of SHE cells by DEHP; however, no clear relationship among induction of peroxisome proliferation, carcinogenicity in vivo and cell transformation was observed. Although the ability to induce cell transformation and chromosomal mutations is not adequate to explain the carcinogenicity of this class of compounds, these biological effects may be contributory to the carcinogenic activities of peroxisome proliferators.
邻苯二甲酸二(2-乙基己基)酯(DEHP)是一种常用的增塑剂,当长期通过饮食给予啮齿动物时,它会诱导肝细胞中过氧化物酶体的增殖并导致肝细胞癌。为了研究DEHP相关癌症的可能机制,我们测量了DEHP和其他过氧化物酶体增殖剂对培养的叙利亚仓鼠胚胎(SHE)细胞的形态转化、染色体畸变和过氧化物酶体增殖的诱导作用。用DEHP及其代谢物单(2-乙基己基)邻苯二甲酸酯(MEHP)处理48小时,对SHE细胞的形态转化诱导作用较弱。使用大鼠肝脏线粒体后上清液进行外源性代谢激活可提高DEHP的转化频率。仅在外源性代谢激活存在的情况下,用DEHP处理24小时才会导致细胞染色体畸变。2-(对氯苯氧基)-2-甲基丙酸乙酯(氯贝丁酯)是一种广泛使用的降血脂药物,未能诱导SHE细胞的形态转化或染色体畸变。用[4-氯-6-(2,3-二甲苯胺基)-2-嘧啶基硫代]乙酸(WY-14,643)处理,它是一种比DEHP或氯贝丁酯更强的致癌物,在外源性代谢激活存在的情况下,其形态转化频率低于DEHP,但在诱导染色体畸变方面比DEHP更活跃。在用DEHP、MEHP、氯贝丁酯或WY-14,643处理2小时的培养物中,通过二氨基联苯胺染色强度测定的过氧化物酶体增殖水平相似。这些结果表明,DEHP代谢物的遗传损伤可能参与了DEHP诱导SHE细胞的细胞转化;然而,未观察到过氧化物酶体增殖诱导、体内致癌性和细胞转化之间的明确关系。虽然诱导细胞转化和染色体突变的能力不足以解释这类化合物的致癌性,但这些生物学效应可能有助于过氧化物酶体增殖剂的致癌活性。